Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate

Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate

Receptor tyrosine kinase-like orphan receptor (ROR2) has been identified as a highly relevant tumor-associated antigen in a variety of cancer indications of high unmet medical need, including melanoma, renal cell carcinoma, osteosarcoma, gastrointestinal stromal tumor, colorectal cancer, pancreatic...

Full description

Saved in:
Bibliographic Details
Main Authors: Hwai Wen Chang, Gerhard Frey, Jing Wang, Haizhen Liu, Charles Xing, Jian Chen, William J. Boyle, Jay M. Short
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:mAbs
Subjects:
ADC
conditionally active
ROR2
tumor targeting
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2025.2490078
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2025.2490078

Similar Items